BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 29356891)

  • 1. High immune cell score predicts improved survival in pancreatic cancer.
    Tahkola K; Mecklin JP; Wirta EV; Ahtiainen M; Helminen O; Böhm J; Kellokumpu I
    Virchows Arch; 2018 Apr; 472(4):653-665. PubMed ID: 29356891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraepithelial Attack Rather than Intratumorally Infiltration of CD8+T Lymphocytes is a Favorable Prognostic Indicator in Pancreatic Ductal Adenocarcinoma.
    Zhang J; Wang YF; Wu B; Zhong ZX; Wang KX; Yang LQ; Wang YQ; Li YQ; Gao J; Li ZS
    Curr Mol Med; 2017; 17(10):689-698. PubMed ID: 29521231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma.
    Mahajan UM; Langhoff E; Goni E; Costello E; Greenhalf W; Halloran C; Ormanns S; Kruger S; Boeck S; Ribback S; Beyer G; Dombroswki F; Weiss FU; Neoptolemos JP; Werner J; D'Haese JG; Bazhin A; Peterhansl J; Pichlmeier S; Büchler MW; Kleeff J; Ganeh P; Sendler M; Palmer DH; Kohlmann T; Rad R; Regel I; Lerch MM; Mayerle J
    Gastroenterology; 2018 Nov; 155(5):1625-1639.e2. PubMed ID: 30092175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma.
    Kiryu S; Ito Z; Suka M; Bito T; Kan S; Uchiyama K; Saruta M; Hata T; Takano Y; Fujioka S; Misawa T; Yamauchi T; Yanagisawa H; Sato N; Ohkusa T; Sugiyama H; Koido S
    BMC Cancer; 2021 Nov; 21(1):1197. PubMed ID: 34758773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
    Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
    Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of CD20 Positive B-Cells and B-Cell Aggregates in the Tumor Infiltration Zone is Associated with Better Survival of Patients with Pancreatic Ductal Adenocarcinoma.
    Brunner M; Maier K; Rümmele P; Jacobsen A; Merkel S; Benard A; Krautz C; Kersting S; Grützmann R; Weber GF
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32150869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis.
    Neuzillet C; Couvelard A; Tijeras-Raballand A; de Mestier L; de Gramont A; Bédossa P; Paradis V; Sauvanet A; Bachet JB; Ruszniewski P; Raymond E; Hammel P; Cros J
    Histopathology; 2015 Nov; 67(5):664-76. PubMed ID: 25809563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-Helper 1 Immune Response in Metastatic Lymph Nodes of Pancreatic Ductal Adenocarcinoma: A Marker For Prolonged Survival.
    Nizri E; Sternbach N; Bar-David S; Ben-Yehuda A; Gerstenhaber F; Ofir T; Wolf I; Weiner G; Lahat G; Klausner J
    Ann Surg Oncol; 2018 Feb; 25(2):475-481. PubMed ID: 29124488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune cell score in pancreatic cancer-comparison of hotspot and whole-section techniques.
    Tahkola K; Leppänen J; Ahtiainen M; Väyrynen J; Haapasaari KM; Karttunen T; Kellokumpu I; Helminen O; Böhm J
    Virchows Arch; 2019 Jun; 474(6):691-699. PubMed ID: 30843106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue microarrays.
    Tewari N; Zaitoun AM; Arora A; Madhusudan S; Ilyas M; Lobo DN
    BMC Cancer; 2013 Sep; 13():436. PubMed ID: 24063854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Impact of the Immune Microenvironment in Spinal Chordoma: Immunoscore as an Independent Favorable Prognostic Factor.
    Zou MX; Lv GH; Wang XB; Huang W; Li J; Jiang Y; She XL
    Neurosurgery; 2019 Jun; 84(6):E318-E333. PubMed ID: 30032257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-Infiltrating B- and T-Cell Repertoire in Pancreatic Cancer Associated With Host and Tumor Features.
    Pineda S; López de Maturana E; Yu K; Ravoor A; Wood I; Malats N; Sirota M
    Front Immunol; 2021; 12():730746. PubMed ID: 34630409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B7-H4 is a prognostic biomarker for poor survival in patients with pancreatic cancer.
    Shen L; Qian Y; Wu W; Weng T; Wang FXC; Hong B; Wu Z; Wang Q; Sang Y; Zhang H; Zhou X; Yao H
    Hum Pathol; 2017 Aug; 66():79-85. PubMed ID: 28600225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of CD73 expression and its relationship to PD-L1 in patients with radically treated pancreatic cancer.
    Tahkola K; Ahtiainen M; Kellokumpu I; Mecklin JP; Laukkarinen J; Laakkonen J; Kenessey I; Jalkanen S; Salmi M; Böhm J
    Virchows Arch; 2021 Feb; 478(2):209-217. PubMed ID: 32676968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perineural Invasion Reprograms the Immune Microenvironment through Cholinergic Signaling in Pancreatic Ductal Adenocarcinoma.
    Yang MW; Tao LY; Jiang YS; Yang JY; Huo YM; Liu DJ; Li J; Fu XL; He R; Lin C; Liu W; Zhang JF; Hua R; Li Q; Jiang SH; Hu LP; Tian GA; Zhang XX; Niu N; Lu P; Shi J; Xiao GG; Wang LW; Xue J; Zhang ZG; Sun YW
    Cancer Res; 2020 May; 80(10):1991-2003. PubMed ID: 32098780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNFSF9 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Pancreatic Cancer.
    Wu J; Wang Y; Jiang Z
    J Gastrointest Cancer; 2021 Mar; 52(1):150-159. PubMed ID: 32077004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.
    Ye HL; Li DD; Lin Q; Zhou Y; Zhou QB; Zeng B; Fu ZQ; Gao WC; Liu YM; Chen RW; Li ZH; Chen RF
    World J Gastroenterol; 2015 Jun; 21(21):6621-30. PubMed ID: 26074700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct Stromal and Immune Features Collectively Contribute to Long-Term Survival in Pancreatic Cancer.
    Sadozai H; Acharjee A; Eppenberger-Castori S; Gloor B; Gruber T; Schenk M; Karamitopoulou E
    Front Immunol; 2021; 12():643529. PubMed ID: 33679807
    [No Abstract]   [Full Text] [Related]  

  • 20. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
    Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
    BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.